2024-511151-18-01招募中1 期
Takeda Brentuximab; Molecular Imaging of Zirconium-89-labeled Brentuximab as a Tool to Investigate brentuximab biodistribution in CD30-positive Lymphoma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
I.Kraai
Scientific
Universitair Medisch Centrum Groningen
研究点 (1)
Loading locations...
相似试验
招募中
4 期
Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell LymphomaHemophagocytic LymphohistiocytosisNCT07270835The First Affiliated Hospital of Soochow University40
尚未招募
2 期
A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström MacroglobulinemiaNCT07259122Institute of Hematology & Blood Diseases Hospital, China43
招募中
1 期
Trastuzumab Deruxtecan, and pembrolizumab in participants with Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer2023-509866-39-00Daiichi Sankyo Inc.76
招募中
2 期
Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard TreatmentNCT07275216City of Hope Medical Center23
招募中
2 期
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell LymphomaMantle Cell LymphomaNCT07261163Institute of Hematology & Blood Diseases Hospital, China37